Personalized Navigation Boosts Hereditary Cancer Genetic Testing Among Relatives

When a person is diagnosed with a BRCA1 or BRCA2 mutation, the discovery ripples far beyond one patient. Each first-degree relative — parents, siblings and children — faces a fifty-fifty chance of having inherited the same variant, and with it a substantially elevated lifetime risk of breast, ovarian, prostate and other cancers. Yet in clinical practice, a striking number of these at-risk relatives never follow through with genetic testing, even after being informed of their potential risk. A new randomized trial from The University of Texas MD Anderson Cancer Center, published in the Journal of Clinical Oncology, suggests that a structured, human-centered approach can close much of that gap, nearly doubling testing uptake within six months and pushing completion rates to ninety percent by eighteen months.

The study enrolled 286 first-degree relatives of 151 individuals who had recently been identified as carriers of BRCA1 or BRCA2 mutations. Participants were randomly assigned to one of two pathways. The first was standard of care, in which relatives received a family notification letter alerting them to the mutation in their family and the availability of testing. The second was a facilitated testing program that combined navigation support with streamlined access to genetic testing services. Navigators guided participants through each step of the process, from understanding what the test involves to scheduling appointments and resolving logistical obstacles. The contrast in outcomes between the two groups was immediate and substantial.

At six months, genetic testing uptake among relatives in the facilitated testing group had risen to 73 percent, compared with 51 percent among those who received the standard notification letter — a 43 percent relative increase in testing. By eighteen months, 90 percent of relatives in the facilitated testing group had completed genetic testing. These numbers matter because cascade genetic testing, the systematic process of offering testing to family members of a known mutation carrier, is one of the most powerful tools in precision oncology. It converts a single molecular diagnosis into a family-wide risk assessment, allowing preventive measures to be targeted precisely at those who need them.

The biological stakes are well established. BRCA1 and BRCA2 are tumor suppressor genes involved in repairing DNA double-strand breaks through homologous recombination. When one copy of either gene carries a pathogenic mutation, cells lose a critical layer of genomic maintenance, and the accumulation of additional defects can drive malignant transformation. Women with pathogenic BRCA variants face markedly elevated risks of breast and ovarian cancer, while men carrying these mutations face increased risks of prostate cancer and, in the case of BRCA2, male breast cancer. Identifying carriers early opens the door to intensified surveillance, risk-reducing surgery, and in some settings targeted therapeutic strategies should cancer develop.

The trial’s results underscore a point that oncologists and genetic counselors have long suspected: information alone is insufficient. A letter explaining inherited risk, however clearly written, leaves the burden of action entirely on the recipient. Relatives must interpret the implications, contact a provider, verify insurance coverage, arrange testing and then follow up on results. Each step is an opportunity for confusion, delay or abandonment. Concerns about cost, uncertainty about the process and difficulty accessing specialized genetics services are among the barriers that have kept cascade testing rates stubbornly low despite decades of growing genetic literacy.

“This study demonstrates that simply informing relatives of their inherited cancer risk is not enough,” said Roni Wilke, M.D., assistant professor of Gynecologic Oncology & Reproductive Medicine at MD Anderson. “When we provided navigation to help people through the testing process, we noticed a meaningful difference in utilization and how soon people completed their testing. This creates new opportunities to enhance screening, prevention and early intervention for several hereditary cancers.” The quote captures the central design insight of the trial: the intervention did not change what relatives were told, but how they were helped to act on it.

Among the 206 relatives who ultimately completed testing, the yield of clinically significant findings was striking. Forty-six percent were found to carry a BRCA1 or BRCA2 mutation associated with a higher risk of cancer, and of those carriers, 86 percent harbored the same familial BRCA mutation that had been identified in their relative. In other words, nearly half of the tested relatives learned they carried a mutation with direct implications for their own cancer surveillance and prevention, and the overwhelming majority of positive results reflected the known family variant rather than an unrelated one. This confirms that when cascade testing is completed at scale, it reliably identifies the intended at-risk individuals.

The implications extend beyond the BRCA genes themselves. Hereditary cancer syndromes involving other genes, such as those linked to Lynch syndrome and familial polyposis, follow a similar cascade logic: one diagnosis in a family member should trigger systematic risk assessment across the kindred. If navigation and facilitation can lift BRCA cascade testing from roughly half of eligible relatives to nine in ten within eighteen months, the same model could plausibly be adapted to other hereditary cancer pathways, multiplying the preventive value of every positive germline result returned by a clinical genetics laboratory.

From a health systems perspective, the trial addresses a well-documented translational gap. Genetic testing technology has become faster and cheaper, and laboratories routinely return results within weeks, yet the downstream work of reaching relatives has lagged. Family notification letters remain the default in many institutions because they are inexpensive and scalable, but the new data suggest that their passive nature leaves substantial value unrealized. Navigation programs require personnel and coordination, costs that health systems and insurers will need to weigh against the potential savings from cancers prevented or detected at earlier, more treatable stages.

For families affected by hereditary cancer, the message of the study is practical and hopeful. Knowing that a BRCA mutation runs in the family is the starting point, not the finish line. Structured support — a navigator who explains the process, helps schedule testing and keeps the momentum going — transformed intention into action for the large majority of relatives in the trial. As genetic information becomes an ever more routine part of cancer care, ensuring that it travels meaningfully through families may prove as important as the sequencing itself, turning individual diagnoses into opportunities for prevention across entire kindreds.

Subject of Research: Cascade genetic testing for hereditary BRCA-related cancers among first-degree relatives

Article Title: Personalized support and navigation increased genetic testing of hereditary cancers among immediate family members

Article References: Personalized support and navigation increased genetic testing of hereditary cancers among immediate family members. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: BRCA1, BRCA2, cascade genetic testing, hereditary cancer, genetic counseling, patient navigation, cancer prevention, MD Anderson Cancer Center, Journal of Clinical Oncology, randomized trial, first-degree relatives, precision oncology